logo
Twitter
Discord
Email
logo
DocGo Inc.

DocGo Inc.

NASDAQ•DCGO
CEO: Mr. Lee Bienstock
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 2020-12-17
DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.
Contact Information
35 West 35th Street, Floor 6, New York, NY, 10001, United States
844-443-6246
www.docgo.com
Market Cap
$90.03M
P/E (TTM)
-5.0
25.9
Dividend Yield
--
52W High
$5.68
52W Low
$0.87
52W Range
1%
Rank38Top 27.7%
4.7
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Average • 4.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2024

Financial Dashboard

Q3 2025 Data

Revenue

$70.81M-48.94%
4-Quarter Trend

EPS

-$0.28-619.48%
4-Quarter Trend

FCF

$101.16K-99.66%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Drops 50.1% Total revenues $247.3M for nine months, down $248.4M due to migrant services wind-down completion.
Net Loss Widens Significantly Stockholders' net loss reached $(48.3)M for nine months, reversing prior $23.2M income reported.
Operating Cash Flow Strong Net cash provided by operating activities was $44.9M despite reporting net loss for nine months period.
Acquired SteadyMD Completed acquisition of SteadyMD for $12.5M cash plus contingent consideration in October 2025.

Risk Factors

Migrant Revenue Wind-Down Mobile Health revenues fell 72.5% (9M 2025) due to migrant services contract completion in prior periods.
Asset Impairment Charges Recorded $16.7M non-cash impairment for goodwill and intangibles during Q3 2025 assessment period.
Customer Concentration Risk Two customers accounted for 41% of 3-month 2024 revenue; concentration remains a key factor.
Government Contract Uncertainty Reliance on government contracts subjects revenue to audits, investigations, and potential policy shifts.

Outlook

2026 Revenue Expectation Expect Mobile Health revenues lower in 2026 due to absence of expected migrant project revenues.
Liquidity Position Secure Anticipates existing cash ($73.4M) and Revolving Facility sufficient for operating needs next twelve months.
Technology Investment Focus Intent to invest in R&D for innovative software services and platform optimization going forward.
Credit Facility Unused Revolving Facility of $55.0M remains unused as of September 30, 2025; no outstanding borrowings reported.

Peer Comparison

Revenue (TTM)

Lucid Diagnostics Inc.LUCD
$1.21B
+28885.2%
DocGo Inc.DCGO
$368.09M
-47.0%
biote Corp.BTMD
$195.65M
+1.3%

Gross Margin (Latest Quarter)

The Joint Corp.JYNT
83.3%
-7.3pp
biote Corp.BTMD
71.8%
+1.3pp
Apyx Medical CorporationAPYX
64.4%
+3.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
APYX$148.06M-10.2-153.8%8.0%
ANIK$137.94M-4.2-22.1%12.0%
JYNT$132.55M-138.6-4.6%3.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-16.3%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 26, 2026
|
EPS:-$0.10
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 10, 2025|
    Revenue: $70.81M-48.9%
    |
    EPS: $-0.28-619.5%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $80.42M-51.2%
    |
    EPS: $-0.11-271.6%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $96.03M-50.0%
    |
    EPS: $-0.09-184.2%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $616.56M-1.2%
    |
    EPS: $0.20+201.7%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $138.68M-25.7%
    |
    EPS: $0.05+17.4%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 7, 2024|
    Revenue: $164.95M+31.4%
    |
    EPS: $0.06-430.4%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $192.09M+70.0%
    |
    EPS: $0.11-425.4%
    Beat

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 28, 2024|
    Revenue: $624.29M+41.7%
    |
    EPS: $0.07-80.5%
    Miss